DB01116ApprovedInvestigationalSmall molecule
A nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery.
- Mechanism
- Curator reviewed
Trimethaphan is a ganglionic blocking agent prevents stimulation of postsynaptic receptors by competing with acetylcholine for these receptor sites. Additional effects may include direct peripheral vasodilation and release of histamine. Trimethaphan's hypotensive effect is due to reduction in sympathetic tone and vasodilation, and is primarily postural.
- Primary indication
- For the controlled reduction of blood pressure during surgery and in the treatment of hypertensive emergencies.Curator reviewed
- Formula / weight
- C22H25N2OS · 365.512 g/mol (avg)
- Also known as
- Thimethaphan · Trimetaphan · Trimetaphanum
Resolves to
Clinical / RWD
Structure
InChIKey
CHQOEHPMXSHGCL-UHFFFAOYSA-NSMILESO=C1N(CC2=CC=CC=C2)C2C[S+]3CCCC3C2N1CC1=CC=CC=C1Targets
What you can answer from here — as of September 23, 2026
2Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Trimethaphan, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account